Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through the loss of exclusivity and 15% royalties on sales of vorasidenib in the US from first commercial sale through the loss of exclusivity The acquisition […]Read More
Shots: Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in H1’21 The agreement includes the transfer of 5 facilities & ~280 employees globally. This transaction will help the BTG specialty pharma business enhance its potential […]Read More
Shots: STADA to acquire GSK’s 15 well-established consumer healthcare brands including Venoruton, for venous treatment, Coldrex cold remedy, Cetebe vitamin C supplements, Mebucaine sore throat range and Tavegyl allergy brand The acquisition will strengthen STADA’s OTC portfolio and accelerates its growth in European countries. The transaction is expected to be completed in Q2’2020 The acquisition […]Read More
Shots: Zentiva acquires Alvogen’s CEE market consisting of 200+ generics and OTC therapies across multiple therapeutics areas which include brands like Lactacyd, Persen, EuBiotic. The transaction is expected to be closed in Q1’20 The focus of the acquisition is to combine two leading branded generics and OTC business in the CEE region and will strengthen […]Read More
Shots: Elanco acquires Bayer’s animal health business in cash & stock transaction, making a total deal value $7.6B. Bayer to get $5.32B cash as up front and $2.28B/~68M as Elanco’s common share with the expected closure of transaction in mid-2020 The focus of the acquisition is to strengthen & accelerating Elanco’s IPP strategy through a […]Read More
Shots: Pfizer’s is expected to spin-off Upjohn and combine with Mylan in all-stock Reverse Morris Trust transaction, with each Mylan share to be converted into one share of the new company. Pfizer will hold 57% share while Mylan will hold 43% share of the newly formed company The merger will allow the new company to […]Read More
Shots: Novartis plans spin-off of its eye care business with an expected 100% spin-off on Apr 9, 2019 and has secured debt financing of $3.5B through banks Novartis stockholder to receive Alcon share for every 5 Novartis shares/ADRs prior to the closing of trade on Apr 8, 2019 and will be listed on SIX and […]Read More
Shots: Perrigo’s separated business helps it to lead the main focus on consumer business, which includes generic medicines including topical creams, foams, mousses, gels, liquids and inhalable products It may include a tax-efficient separation to shareholders, a sale or merger with no assurance as to form and timing of transaction This separation of […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
